
Climb Bio, Inc. (NASDAQ:CLYM – Free Report) – Stock analysts at HC Wainwright raised their FY2026 earnings per share (EPS) estimates for Climb Bio in a research note issued on Monday, November 9th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($0.74) per share for the year, up from their previous forecast of ($0.76). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Climb Bio’s current full-year earnings is ($0.75) per share. HC Wainwright also issued estimates for Climb Bio’s Q4 2026 earnings at ($0.18) EPS, Q3 2027 earnings at ($0.25) EPS, Q4 2027 earnings at ($0.26) EPS and FY2027 earnings at ($0.97) EPS.
Climb Bio (NASDAQ:CLYM – Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.02.
Read Our Latest Research Report on Climb Bio
Climb Bio Trading Down 11.3%
CLYM opened at $10.87 on Wednesday. Climb Bio has a 12-month low of $1.63 and a 12-month high of $18.33. The business’s fifty day simple moving average is $11.66 and its 200-day simple moving average is $10.60. The company has a market capitalization of $638.50 million, a price-to-earnings ratio of -13.26 and a beta of 0.01.
Insider Activity
In other news, Director Stephen Thomas sold 100,000 shares of Climb Bio stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $13.67, for a total value of $1,367,000.00. Following the transaction, the director directly owned 467,969 shares in the company, valued at approximately $6,397,136.23. This trade represents a 17.61% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 2.60% of the company’s stock.
Institutional Investors Weigh In On Climb Bio
A number of hedge funds have recently made changes to their positions in CLYM. First Trust Advisors LP purchased a new stake in shares of Climb Bio during the third quarter valued at about $490,000. State Street Corp boosted its holdings in shares of Climb Bio by 34.7% in the 3rd quarter. State Street Corp now owns 1,850,010 shares of the company’s stock valued at $21,220,000 after buying an additional 476,466 shares in the last quarter. Fisher Asset Management LLC bought a new stake in shares of Climb Bio in the 3rd quarter valued at about $505,000. Nan Fung Trinity HK Ltd. grew its position in shares of Climb Bio by 212.3% in the 3rd quarter. Nan Fung Trinity HK Ltd. now owns 360,654 shares of the company’s stock worth $4,137,000 after buying an additional 245,160 shares during the last quarter. Finally, Fifth Third Bancorp grew its position in shares of Climb Bio by 10.1% in the 3rd quarter. Fifth Third Bancorp now owns 181,510 shares of the company’s stock worth $2,082,000 after buying an additional 16,587 shares during the last quarter. 69.76% of the stock is currently owned by hedge funds and other institutional investors.
Climb Bio Company Profile
Climb Bio is a clinical-stage biopharmaceutical company developing treatments for autoimmune and inflammatory diseases, with a focus on conditions involving B cells and antibody production. Its lead candidate, budoprutug, is an antibody designed to engage CD19 and FcγRIIb to inhibit B-cell activity. The company is evaluating the candidate in clinical studies for immune-mediated diseases, including immune thrombocytopenia and membranous nephropathy. Climb Bio is also developing CLYM-116, an antibody targeting APRIL, a protein involved in B-cell and antibody activity.
Featured Articles
- Five stocks we like better than Climb Bio
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for Climb Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Climb Bio and related companies with MarketBeat.com's FREE daily email newsletter.
